Modified J-Chain Antibodies for ADME-Controlled Avidity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing monoclonal IgG antibodies used in immune checkpoint blockade therapies have limited therapeutic index due to immune-related adverse events and suboptimal pharmacokinetics, necessitating the development of binding molecules with improved avidity and controlled ADME characteristics.
Innovation Solution
Modification of the J-chain in IgM, IgA, IgG/IgM, or IgG/IgA antibodies with ADME-modulating moieties, such as albumin-binding peptides or transferrin receptor ligands, to enhance concentration, half-life, and tissue distribution, allowing for increased avidity and reduced clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal IgG antibodies are used in immune checkpoint blockade therapies, then therapeutic efficacy is achieved, but immune-related adverse events occur and pharmacokinetics are suboptimal
Solution Approach 1:
The patent changes the isotype parameter from IgG to IgM or IgA, which fundamentally alters the pharmacokinetic and pharmacodynamic parameters of the antibody. IgM and IgA exhibit different clearance rates, half-lives, and tissue distribution patterns compared to IgG, thereby improving the therapeutic index by maintaining efficacy while reducing adverse events
Solution Approach 2:
The patent creates composite antibody structures by combining IgM or IgA with modified J-chains that incorporate ADME-modulating moieties. This composite structure integrates the therapeutic binding function with enhanced pharmacokinetic properties, achieving both efficacy and improved safety profile
2Reliability
If monoclonal IgG antibodies are used in immune checkpoint blockade therapies, then therapeutic efficacy is achieved, but pharmacokinetics are suboptimal
Solution Approach 1:
The patent changes the isotype parameter from IgG to IgM or IgA, which fundamentally alters the pharmacokinetic parameters including half-life and clearance rate. IgM and IgA exhibit different elimination kinetics compared to IgG, thereby improving the therapeutic index by maintaining efficacy while optimizing duration of action
3Quantity of substance
If J-chain is modified with ADME-modulating moieties, then concentration and half-life are enhanced, but structural complexity increases
Solution Approach 1:
The J-chain serves as an intermediary component that connects the antibody's therapeutic function with ADME optimization. By modifying the J-chain with ADME-modulating moieties such as albumin-binding domains or FcRn-binding sequences, the patent enhances concentration and half-life while maintaining the overall modular structure of the antibody molecule
Solution Approach 2:
The modified J-chain performs multiple functions: it facilitates polymeric assembly of IgM or IgA, provides structural stability, and incorporates ADME-modulating moieties to enhance pharmacokinetics. This multi-functionality reduces the need for separate optimization components, thereby managing structural complexity
Data Source
AI summary
The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.